Athernal Bio - About the company
Athernal Bio is a series A company based in Babraham (United Kingdom), founded in 2024 by Nirupa Desai and Leuan Walker. It operates as a Developer of vaccines to target and lower the risk of cancer and other age-related diseases. Athernal Bio has raised $4.7M in funding from Delin Ventures. The company has 240 active competitors, including 71 funded and 76 that have exited. Its top competitors include companies like Fulcrum Therapeutics, Odyssey and NextCure.
Company Details
Developer of vaccines to target and lower the risk of cancer and other age-related diseases. The company is developing immunotherapies for high-risk clonal haematopoiesis addressing blood cancer precursor condition with the aim of stopping cancer before it starts through early and proactive therapeutic intervention.
- Website
- www.athernalbio.com/
- Email ID
- *****@athernalbio.com
Key Metrics
Founded Year
2024
Location
Babraham, United Kingdom
Stage
Series A
Total Funding
$4.7M in 2 rounds
Latest Funding Round
Investors
Ranked
177th among 240 active competitors
Similar Companies
Sign up to download Athernal Bio's company profile
Athernal Bio's funding and investors
Athernal Bio has raised a total funding of $4.7M over 2 rounds. Its first funding round was on Oct 01, 2025. Its latest funding round was a Grant (prize money) round on Sep 14, 2026 for $*****. 1 investor participated in its latest round. Athernal Bio has 1 institutional investor.
Here is the list of recent funding rounds of Athernal Bio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 14, 2026 | 9692779 | Grant (prize money) | 3864418 | 8090423 | 4581861 | 7262380 |
Oct 01, 2025 | 9121587 | Series A | 6185577 | 6515456 | 4023824 |
Access funding benchmarks and valuations. Sign up today!View details of Athernal Bio's funding rounds and investors
Athernal Bio's founders and board of directors
Founder? Claim ProfileThe founders of Athernal Bio are Nirupa Desai and Leuan Walker. Colin Freund and Colin Freund are the CEOs of Athernal Bio.
Here are the details of Athernal Bio's key team members:
- Nirupa Desai: Co-Founder of Athernal Bio. Contact Info: 1 email address
- Leuan Walker: Former Co-Founder of Athernal Bio. Contact Info: 1 email address
- Colin Freund: CEO of Athernal Bio. Contact Info: 1 email address
- Colin Freund: CEO of Athernal Bio.
View details of Athernal Bio's Founder profiles and Board Members
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Athernal Bio's Competitors and alternates
Top competitors of Athernal Bio include Fulcrum Therapeutics, Odyssey and NextCure. Here is the list of Top 10 competitors of Athernal Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Fulcrum Therapeutics 2015, Cambridge (United States), Public | Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | $115M | 71/100 | |
2nd |  Odyssey 2018, Cambridge (United States), Public | Developer of immunotherapeutics for immunological and cancer diseases | $717M | 66/100 | |
3rd | NextCure 2015, New Haven (United States), Public | Developer of next-generation immuno-oncology-based drugs | $175M | 66/100 | |
4th | Ossium Health 2016, San Francisco (United States), Series C | Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning | $125M | 65/100 | |
5th | Compass Therapeutics 2013, Cambridge (United States), Public | Antibody discovery and development company | $239M | 65/100 | |
6th | Rigel 1996, San Francisco (United States), Public | Developer of drugs for hematologic disorders, cancer, and rare immune disease | - | 64/100 | |
7th | Ajax 2019, Cambridge (United States), Acquired | Developer of targeted therapies for the treatment of hematologic malignancies | $135M | 64/100 | |
8th | Orca Bio 2016, Menlo Park (United States), Series F | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | $300M | 63/100 | |
9th | _1591332761406.jpg?devicePixelRatio=2&height=30&width=30){kind=logo} Editas Medicine 2013, Cambridge (United States), Public | Developer of therapeutics for rare genetic diseases | $210M | 63/100 | |
10th |  Eureka Therapeutics 2006, Emeryville (United States), Series E | Biopharmaceutical firm pioneering T-cell therapies for solid tumors and malignancies | $176M | 62/100 | |
177th |  Athernal Bio 2024, Babraham (United Kingdom), Series A | Developer of vaccines to target and lower the risk of cancer and other age-related diseases | $4.7M | 27/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Athernal Bio's competitors? Click here to see the top ones
Athernal Bio's Investments and acquisitions
Athernal Bio has made no investments or acquisitions yet.
Reports related to Athernal Bio
Here is the latest report on Athernal Bio's sector:
Are you a Founder ?
FAQs about Athernal Bio
Explore our recently published companies
- VerTalent - Atlanta based, Unfunded company
- Digital Business Hub - Unfunded company
- ROKA Multisport - Unfunded company
- Optical Pop - Salt Lake City based, 2024 founded, Unfunded company
- Veterans Cricket India Association - Dubai based, 2019 founded, Unfunded company
- Finaya - Barueri based, 2023 founded, Unfunded company
